Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395:2008–20.

Article  CAS  PubMed  Google Scholar 

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.

Article  Google Scholar 

Eshmuminov D, Aminjonov B, Palm RF, et al. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol. 2023;30:4417–28.

Article  PubMed  PubMed Central  Google Scholar 

Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.

Article  CAS  PubMed  Google Scholar 

Inoue Y, Saiura A, Oba A, et al. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021;28:143–55.

Article  PubMed  Google Scholar 

Conroy T, Lambert A, Ducreux M. Adjuvant and neoadjuvant approaches in pancreatic cancer. Curr Opin Oncol. 2023;35:326–33.

Article  CAS  PubMed  Google Scholar 

de Geus SWL, Sachs TE. A paradigm shifts: neoadjuvant therapy for clearly resectable pancreatic cancer. Ann Surg Oncol. 2023;30:3427–36.

Article  PubMed  Google Scholar 

Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20:318–37.

Article  PubMed  Google Scholar 

Japan Pancreatic Society: Classification of Pancreatic Carcinoma. 4th English edn. Kanehara & Co., Ltd.; 2017. http://www.suizou.org/pdf/Classification_of_Pancreatic_Carcinoma_4th_Engl_ed.pdf

Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.

Article  CAS  PubMed  Google Scholar 

Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–47.

Article  PubMed  PubMed Central  Google Scholar 

Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77.

Article  CAS  PubMed  Google Scholar 

Shibata Y, Uemura K, Sumiyoshi T, et al. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg. 2023;408:280.

Article  PubMed  Google Scholar 

Kim YI, Song KB, Lee YJ, et al. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg. 2019;106:898–909.

Article  CAS  PubMed  Google Scholar 

Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.

Article  CAS  PubMed  Google Scholar 

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

Article  CAS  PubMed  Google Scholar 

Yasuda S, Nagai M, Terai T, et al. Essential updates 2021/2022: surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2023;7:358–66.

Article  PubMed  PubMed Central  Google Scholar 

Satoi S, Yamaue H, Kato K, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20:590–600.

Article  PubMed  Google Scholar 

Ushida Y, Inoue Y, Ito H, et al. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology. 2021;21:130–7.

Article  CAS  PubMed  Google Scholar 

Takeda T, Sasaki T, Okamoto T, et al. Outcomes of pancreatic cancer with liver oligometastasis. J Hepatobiliary Pancreat Sci. 2023;30:229–39.

Article  PubMed  Google Scholar 

Sakaguchi T, Valente R, Tanaka K, et al. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: a review of current literature. Pancreatology. 2019;19:672–80.

Article  PubMed  Google Scholar 

Schwarz C, Fitschek F, Primavesi F, et al. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol. 2020;35:169–73.

Article  CAS  PubMed  Google Scholar 

Mitsuka Y, Yamazaki S, Yoshida N, et al. Time interval-based indication for liver resection of metastasis from pancreatic cancer. World J Surg Oncol. 2020;18:294.

Article  PubMed  PubMed Central  Google Scholar 

Dünschede F, Will L, von Langsdorf C, et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res. 2010;44:209–13.

Article  PubMed  Google Scholar 

Thomas RM, Truty MJ, Nogueras-Gonzalez GM, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696–704.

Article  PubMed  Google Scholar 

Zanini N, Lombardi R, Masetti M, et al. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg. 2015;67:19–25.

Article  PubMed  Google Scholar 

Hackert T, Niesen W, Hinz U, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358–63.

Article  CAS  PubMed  Google Scholar 

Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.

Article  PubMed  Google Scholar 

Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787–95.

Article  PubMed  PubMed Central  Google Scholar 

Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268–74.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Cheng S, Fathy AH, et al. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther. 2018;11:1899–908.

Article  PubMed  PubMed Central  Google Scholar 

Riauka R, Ignatavicius P, Barauskas G. Preoperative platelet to lymphocyte ratio as a prognostic factor for resectable pancreatic cancer: a systematic review and meta-analysis. Dig Surg. 2020;37:447–55.

Article  PubMed  Google Scholar 

Wang DS, Luo HY, Qiu MZ, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29:3092–100.

Article  CAS  PubMed  Google Scholar 

Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcea G, Ladwa N, Neal CP, et al. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35:868–72.

Article  CAS  PubMed  Google Scholar 

Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104:726–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ushida Y, Inoue Y, Oba A, et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-center retrospective study. Ann Surg Oncol. 2022;29:5038–50.

Article  PubMed